An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?

Nat Biotechnol. 2019 Jan 3;37(1):21-22. doi: 10.1038/nbt.4324.

Authors

Timo Minssen¹, Aaron S Kesselheim², Jonathan J Darrow²

Affiliations

¹ Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), University of Copenhagen, Denmark.
² Harvard Medical School and Brigham & Women's Hospital, Boston, Massachusetts, USA.

PMID: 30605154
DOI: 10.1038/nbt.4324

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biosimilar Pharmaceuticals
Biotechnology / legislation & jurisprudence*
Commerce*
Drug Industry / legislation & jurisprudence*
Drug and Narcotic Control
Drugs, Generic
Europe
Humans
Patents as Topic*
Pharmaceutical Preparations / economics
United States

Substances

Biosimilar Pharmaceuticals
Drugs, Generic
Pharmaceutical Preparations